title: Initial improvements when converting eyes with treatment-resistant exudative AMD to aflibercept are substantially diminished after increasing treatment intervals from 4 to 8 weeks.
authors.affiliation: Department of Ophthalmology, Oslo University Hospital and University of Oslo, Oslo, Norway.
authors.forename: Øystein Kalsnes
authors.initials: ØK
authors.lastname: Jørstad
authors.affiliation: Department of Ophthalmology, Oslo University Hospital and University of Oslo, Oslo, Norway.
authors.forename: Rowan Thomas
authors.initials: RT
authors.lastname: Faber
authors.affiliation: Department of Ophthalmology, Oslo University Hospital and University of Oslo, Oslo, Norway.
authors.forename: Morten Carstens
authors.initials: MC
authors.lastname: Moe
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000068258:Bevacizumab / Q000627:therapeutic use; D004351:Drug Resistance; D057915:Drug Substitution; D006801:Humans; D058449:Intravitreal Injections; D000069579:Ranibizumab / Q000627:therapeutic use; D040262:Receptors, Vascular Endothelial Growth Factor / Q000627:therapeutic use*; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use*; D058471:Subretinal Fluid / Q000187:drug effects; D013997:Time Factors; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D057135:Wet Macular Degeneration / Q000188:drug therapy* / Q000503:physiopathology
chemical_list: D020533:Angiogenesis Inhibitors; D011993:Recombinant Fusion Proteins; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; C533178:aflibercept; D000068258:Bevacizumab; D040262:Receptors, Vascular Endothelial Growth Factor; D000069579:Ranibizumab